Albania
Bośnia i Hercegowina
Bułgaria
Chorwacja
Cypr
Czarnogóra
Czechy
Dania
Estonia
Hiszpania
Kosowo
Litwa
Łotwa
Luksemburg
Macedonia
Niemcy
Polska
Portugalia
Rumunia
Serbia
Słowacja
Słowenia
Szwajcaria
Szwecja
Turcja
Węgry
Wielka Brytania
Włochy
UAE
Hong Kong
Kuwejt
Liban
RPA
Terapie
komórkami macierzystymi
Terapie komórkami macierzystymi
Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).
Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.
Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.
Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.
Data aktualizacji: 06.2026
Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
| Lp. | Źródło | Typ źródła | Wskazanie | Obszar medycyny | Rok podania | Terapia | Kraj | Wiek odbiorcy |
|---|---|---|---|---|---|---|---|---|
| 1401 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Germany | 21 |
| 1402 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Denmark | 65 |
| 1403 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Romania | 25 |
| 1404 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Italy | 27 |
| 1405 | Apheresis | Allogeneic | Polycythaemia Vera | Hematology | 2025 | Standard Therapy | Germany | 61 |
| 1406 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 25 |
| 1407 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 51 |
| 1408 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 1409 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 53 |
| 1410 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Lithuania | 61 |
| 1411 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Russian Federation | 49 |
| 1412 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 36 |
| 1413 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 62 |
| 1414 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 54 |
| 1415 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 74 |
| 1416 | Apheresis | Allogeneic | NHL Non-Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | Poland | 49 |
| 1417 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 62 |
| 1418 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2025 | Standard Therapy | USA | 74 |
| 1419 | Apheresis | Allogeneic | NHL Non-Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | Argentine | 57 |
| 1420 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 56 |
| 1421 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Belgium | 71 |
| 1422 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Spain | 59 |
| 1423 | Apheresis | Allogeneic | Other Myelofibrosis/Myelosclerosis | Hematology | 2025 | Standard Therapy | USA | 65 |
| 1424 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 14 |
| 1425 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Denmark | 57 |
| 1426 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 1427 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 51 |
| 1428 | Apheresis | Allogeneic | Richter Transformation CDLBCC | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 1429 | Apheresis | Allogeneic | Acute Myelogenous Leukemia-MR | Hematology | 2025 | Standard Therapy | Russian Federation | 16 |
| 1430 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 63 |
| 1431 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 66 |
| 1432 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 50 |
| 1433 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 38 |
| 1434 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 43 |
| 1435 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 74 |
| 1436 | Apheresis | Allogeneic | T-cell Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 51 |
| 1437 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 59 |
| 1438 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 66 |
| 1439 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 1440 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 33 |
| 1441 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 48 |
| 1442 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Netherlands | 66 |
| 1443 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 57 |
| 1444 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Belgium | 56 |
| 1445 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 55 |
| 1446 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 24 |
| 1447 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Italy | 61 |
| 1448 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 71 |
| 1449 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Canada | 53 |
| 1450 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1451 | Apheresis | Autologous | Mantle Cell Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 45 |
| 1452 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Germany | 61 |
| 1453 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Germany | 32 |
| 1454 | Apheresis | Autologous | Diffuse Large B-Cell Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1455 | Apheresis | Autologous | Central Nervous System Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 75 |
| 1456 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 1457 | Cord Tissue | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 6 |
| 1458 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2024 | Experimental Therapy | Romania | 6 |
| 1459 | Cord Tissue | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 4 |
| 1460 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2024 | Experimental Therapy | Romania | 6 |
| 1461 | Cord Tissue | Allogeneic – Unrelated | Degenerative and Traumatic Cartilage | Orthopedics | 2024 | Experimental Therapy | Poland | 50 |
| 1462 | Cord Tissue | Allogeneic – Unrelated | Degenerative and Traumatic Cartilage | Orthopedics | 2024 | Experimental Therapy | Poland | 49 |
| 1463 | Cord Tissue | Allogeneic – Unrelated | Degenerative and Traumatic Cartilage | Orthopedics | 2024 | Experimental Therapy | Poland | 58 |
| 1464 | Cord Tissue | Allogeneic – Unrelated | Graft Versus Host Disease | Hematology | 2024 | Experimental Therapy | Poland | 7 |
| 1465 | Cord Tissue | Allogeneic – Unrelated | Graft Versus Host Disease | Hematology | 2024 | Experimental Therapy | Poland | 15 |
| 1466 | Cord Tissue | Allogeneic – Unrelated | Ovarian Dysfunction | Gynecology | 2024 | Experimental Therapy | Poland | 48 |
| 1467 | Cord Tissue | Allogeneic – Related | Severe Pulmonary Hypertension +Mitral Regurgitation | Cardiovascular/Pulmonary | 2024 | Experimental Therapy | Romania | 2 |
| 1468 | Cord Tissue | Allogeneic – Unrelated | Amyotrophic lateral sclerosis | Neurology | 2024 | Experimental Therapy | Poland | 57 |
| 1469 | Cord Tissue | Allogeneic – Unrelated | Degenerative and traumatic cartilage damage | Orthopedics | 2024 | Experimental Therapy | Poland | 68 |
| 1470 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2024 | Experimental Therapy | Romania | 17 |
| 1471 | Cord Tissue | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 7 |
| 1472 | Cord Tissue | Allogeneic – Unrelated | Degenerative and traumatic cartilage damage | Orthopedics | 2024 | Experimental Therapy | Poland | 61 |
| 1473 | Cord Tissue | Allogeneic – Unrelated | Degenerative and traumatic cartilage damage | Orthopedics | 2024 | Experimental Therapy | Poland | 45 |
| 1474 | Cord Tissue | Allogeneic – Unrelated | Amyotrophic lateral sclerosis | Neurology | 2024 | Experimental Therapy | Poland | 56 |
| 1475 | Cord Tissue | Allogeneic – Unrelated | Graft-versus-host disease | Hematology | 2024 | Experimental Therapy | Poland | 0 |
| 1476 | Cord Tissue | Allogeneic – Unrelated | Amyotrophic lateral sclerosis | Neurology | 2024 | Experimental Therapy | Poland | 39 |
| 1477 | Cord Tissue | Allogeneic – Unrelated | GvHD | Neurology | 2024 | Experimental Therapy | Poland | 9 |
| 1478 | Cord Tissue | Allogeneic – Unrelated | Cerebral palsy | Neurology | 2024 | Experimental Therapy | Poland | 5 |
| 1479 | Cord Tissue | Allogeneic – Unrelated | Cerebral palsy | Neurology | 2024 | Experimental Therapy | Poland | 13 |
| 1480 | Cord Tissue | Allogeneic – Unrelated | Leukodystrophy | Neurology | 2024 | Experimental Therapy | Poland | 1 |
| 1481 | Cord Tissue | Allogeneic – Unrelated | Cerebral Palsy | Neurology | 2024 | Experimental Therapy | Poland | 7 |
| 1482 | Cord Tissue | Allogeneic – Unrelated | Leukodystrophy | Neurology | 2024 | Experimental Therapy | Poland | 1 |
| 1483 | Cord Tissue | Allogeneic – Unrelated | Cerebellar-spinal ataxia | Neurology | 2024 | Experimental Therapy | Poland | 35 |
| 1484 | Cord Tissue | Allogeneic – Unrelated | Leukodystrophy | Neurology | 2024 | Experimental Therapy | Poland | 1 |
| 1485 | Cord Tissue | Allogeneic – Unrelated | Cerebral Palsy | Neurology | 2024 | Experimental Therapy | Poland | 4 |
| 1486 | Cord Blood | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 11 |
| 1487 | Cord Blood | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 10 |
| 1488 | Cord Blood | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 6 |
| 1489 | Cord Blood | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 4 |
| 1490 | Cord Blood | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Romania | 5 |
| 1491 | Cord Blood | Allogeneic | Cerebral Palsy | Neurology | 2024 | Experimental Therapy | Poland | 3 |
| 1492 | Cord Blood | Allogeneic | Cerebral Palsy | Neurology | 2024 | Experimental Therapy | Poland | 7 |
| 1493 | Cord Blood | Autologous | CP | Neurology | 2024 | Experimental Therapy | Hungary | 4 |
| 1494 | Cord Blood | Autologous | Pervasive Developmental Disorder | Neurology | 2024 | Experimental Therapy | Poland | 3 |
| 1495 | Cord Blood | Autologous | Pervasive Developmental Disorder | Neurology | 2024 | Experimental Therapy | Poland | 5 |
| 1496 | Cord Blood | Autologous | Pervasive developmental disorder | Neurology | 2024 | Experimental Therapy | Poland | 4 |
| 1497 | Cord Blood | Allogeneic – Related | fanconi aplastic anemia | Hematology | 2024 | Standard Therapy | Turkey | 12 |
| 1498 | Cord Blood | Autologous | Neuroblastoma | Neurology | 2024 | Standard Therapy | Poland | 4 |
| 1499 | Cord Blood | Autologous | Pervasive developmental disorder | Neurology | 2024 | Experimental Therapy | Poland | 9 |
| 1500 | Cord Blood | Autologous | Autism | Neurology | 2024 | Experimental Therapy | Slovakia | 4 |